No Data
Unblinding of phase II trials led to two consecutive daily limit increases! Fujian Cosunter Pharmaceutical emphasizes uncertainty in the research and development of domestically produced "First-in-class" innovative drugs for hepatitis B. | Speed reading a
After two consecutive 20CM daily limit rises within three trading days, Fujian Cosunter Pharmaceutical quickly issued a notice to put out the fire, emphasizing that there is still uncertainty in the R&D of its first-in-class innovative drug for hepatitis B. Industry experts believe that the positive results of clinical trials and investor sentiment are the main factors affecting the market. Previously, Beigene had introduced a similar pipeline, but there was no follow-up.
Instead of looking at whether or not fines were received, the focus is on how many fines were received, with leading brokerages receiving a high number of fines, mostly from investment banks.
① In the year when Andak Technology, sponsored by Citic Securities, went public, the non-deductible loss was 0.634 billion yuan, and Hengyi Petrochemical's convertible bonds had an operating profit decrease of more than 50% in the year of issuance; ② In Bonam Precision, which terminated its IPO withdrawal, the sponsor did not execute the verification procedure properly and did not carefully check abnormal situations.
Fuxin Dare Automotive Parts' solid state battery is expected to be validated for use? Paired with Jiangling Motors to customize cell samples | Quick Read Announcement.
Fuxin Dare Automotive Parts signed a strategic cooperation agreement with Jiangling New Energy to customize and develop cell samples for solid state batteries and explore the feasibility of mass production. The company's solid state battery products have passed third-party institutions' nail penetration tests, etc.
How to solve the dilemma of the HPV vaccine market? Amid internal and external problems, the market cap of Chongqing Zhifei Biologicals fell below 60 billion yuan.
As of this morning's close, the market cap of Chongqing Zhifei Biological Products has fallen below 60 billion yuan, and the stock price has hit a new low in nearly 5 years. In the first half of the year, sales of Merck's HPV vaccine in China fell, while domestically produced nine-valent HPV vaccines are about to be released. Industry experts believe that Chongqing Zhifei Biological Products will face certain pressures in the next two years.
Intraday Quick Look | Hong Kong stocks opened high and fell low, the technology index fell nearly 1%, network technology and gaming stocks weakened, tencent music fell over 17% after the results.
Most network technology company stocks fell, with Netease falling more than 4%, Tencent falling nearly 2%, Ctrip Group falling more than 1%, while SenseTime, Meituan and others followed suit; Baidu and Bilibili saw a slight increase.
The annual top event of the integrated circuit industry is about to be held, and the recovery of the semiconductor prosperity is expected to continue.
On August 16, 2024, the top annual event in China's integrated circuit industry, the 2024 China (Shenzhen) Integrated Circuit Summit (referred to as the 'ICS2024 Summit'), will be grandly held in Shenzhen. Yongzheng Ma of Shanghai Securities believes that the semiconductors will achieve preliminary repair in 2024H1, and the recovery of the sub-sectors' prosperity is expected to continue in 2024H2.